多西紫杉醇在乳腺癌根治术后化疗中的应用效果及安全性观察

Abstract
Figure/Table
References (28)
Related Citation (15)

Download: PDF (562 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the application effect and safety of Docetaxel in chemotherapy after radical mastectomy. Methods Sixty patients with breast cancer who underwent radical mastectomy in the Second People’s Hospital of Wuhu City, Anhui Province from January 2015 to January 2017 were selected as research subjects. They were divided into two groups according to random number table method, with 30 cases in each group. Control group was given Epirubicin combined with Cyclophosphamide, and observation group was given Docetaxel on the basis of control group. The clinical efficacy and the occurrence degree of toxic side effects were compared between two groups. After treatment, the patients were followed up for three years by telephone. If the patients died, the follow-up was stopped. The survival rates of one to three years after treatment were observed between two groups. Results The total effective rate and disease control rate of observation group were higher than those of the control group, and the differences were statistically significant (P < 0.05). There was no significant difference in the occurrence degree of toxic side effects in digestive system between two groups after treatment (P > 0.05). One and two years after treatment, there were no differences in survival rates between two groups (P > 0.05); three years after treatment, the survival rate of observation group was higher than that of control group, and the difference was statistically significant (P < 0.05). Conclusion Docetaxel chemotherapy after radical mastectomy has significant effect, high safety and good prognosis.

Key words： Docetaxel Epirubicin Cyclophosphamide Radical mastectomy Chemotherapy Toxic side effects Safety

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YUAN Le WAN Xin’an ZHOU Qin

Cite this article:

YUAN Le WAN Xin’an ZHOU Qin. Application effect and safety of Docetaxel in postoperative chemotherapy after radical mastectomy[J]. 中国医药导报, 2021, 18(14): 107-110.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2021/V18/I14/107

[1] 吴小燕.心理护理对乳腺癌根治术患者疼痛感及生活质量影响[J].中华肿瘤防治杂志，2019，26（S1）：187-188.
[2] Zhao X，Yang X，Gao R，et al. HER2-positive pure mucinous breast carcinoma：A case report and literature review [J]. Medicine（Baltimore），2020，99（33）：e20996.
[3] 朱月梅，王国如，张沂，等.表柔比星联合紫杉醇新辅助化疗治疗乳腺癌保乳术患者的疗效及安全性[J].中国普通外科杂志，2019，28（11）：104-111.
[4] Kong H，Chen J，Tang SC. Synchronous papillary thyroid carcinoma and breast ductal carcinoma [J]. J Int Med Res.2020，48（8）：300060520948710.
[5] 曾乌查，施烯，黄铃铃.多西紫杉醇血药浓度监测在乳腺癌化疗中的临床应用[J].福建医科大学学报，2018，52（6）：396-399.
[6] 赵毅玲，王静，唐杰露，等.乳腺癌血流动力学的超声表现与血管内皮生长因子及微血管密度的诊断标准[J].血管与腔内血管外科杂志，2018，4（5）：444-448.
[7] Chen L，Qi H，Zhang L，et al. Effects of FGFR gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-docetaxel-based chemotherapy in breast cancer patients [J]. BMC Cancer，2018，18（1）：1038.
[8] 宁俏，汪盛丹.乳腺癌根治术后放化疗患者集束化护理措施对其心理状况及预后的影响分析[J].中国地方病防治杂志，2017，32（8）：906-908.
[9] 张琴.MSCT对于不同分子分型乳腺癌肝转移瘤的诊断价值[D].银川：宁夏医科大学，2018：1-47.
[10] Al Ja’bari A，Robertson M，El-Boghdadly K，et al. A randomised controlled trial of the pectoral nerves-2（PECS-2）block for radical mastectomy [J]. Anaesthesia，2019，74（10）：1277-1281.
[11] 王薇，别克扎提·再孜提汉，周静，等.多西紫杉醇联合表阿霉素序贯化疗治疗三阴性乳腺癌的效果观察[J].山东医药，2018，58（4）：79-81.
[12] 孙丽.乳腺癌靶向药物的研究及临床应用新进展[J].中国医药科学，2020，10（24）：61-64，82.
[13] Chang JH，Jeon W，Kim K，et al. Prognostic Significance of Inner Quadrant Involvement in Breast Cancer Treated with Neoadjuvant Chemotherapy [J]. J Breast Cancer，2016， 19（4）：394-401.
[14] 毛文娟，么杨.复方苦参注射液对乳腺癌术后AC→T方案化疗的效果及安全性评价[J].辽宁中医杂志，2018， 45（4）：760-762.
[15] Bu QA，Bu JH，Cui T，et al. Observation and analysis of clinical efficacy of breast-conserving therapy integrated with neoadjuvant chemotherapy on Breast Cancer [J]. Pak J Pharm Sci，2018，31（6（Special））：2869-2872.
[16] 王志超.保乳手术与改良根治术对乳腺癌患者并发症及生存预后的影响比较[J].中国现代医生，2021，59（4）：57-60.
[17] 崔沐.白介素1受体相关激酶1在乳腺癌紫杉醇耐受患者治疗中的作用机制[J].影像研究与医学应用，2018， 2（11）：217-218.
[18] 冯雅博，周晖，刘进康.功能磁共振评估乳腺癌新辅助化疗效果的研究进展[J].中国医学影像学杂志，2019， 198（11）：75-78.
[19] Yamashita Y，Tanaka Y，Kono S，et al. Effectiveness of Pertuzumab， Trastuzumab， and Docetaxel Combination Neoadjuvant Chemotherapy for HER2-Positive Inflammatory Breast Cancer：A Case Report [J]. Breast Care，2017， 12（1）：45.
[20] 魏素菊，李海飞，刘义冰，等.化疗对三阴性乳腺癌CD44+CD24-/low细胞亚群的影响[J].肿瘤，2016，31（11）：1016-1021.
[21] 石瑛，任静静，梁晨，等.GSDME通过调控细胞焦亡影响乳腺癌MCF-7细胞对紫杉醇的敏感性[J].中国肿瘤生物治疗杂志，2019，26（2）：146-151.
[22] 张凯，杨天瑶，吕振晔，等.白蛋白紫杉醇联合表柔比星和环磷酰胺治疗乳腺癌的临床研究[J].中国临床药理学杂志，2019，35（5）：428-430，434.
[23] 刘艳翠，赵微，孙平，孙成.培美曲塞+顺铂与多西紫杉醇+替吉奥治疗晚期乳腺癌的效果比较[J].中国当代医药，2019，26（17）：33-35.
[24] 童舟，鲍瑜，章左林.白蛋白结合型紫杉醇和多西他赛治疗HER-2阴性乳腺癌患者的临床疗效比较[J].临床和实验医学杂志，2020，19（19）：2067-2070.
[25] Masuda N，Lee SJ，Ohtani S，et al. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy [J]. N Engl J Med，2017，376（22）：2147-2159.
[26] 张耀，周敬，倪华栋.中西医结合治疗对于乳腺癌术后疗效及临床应用价值[J].中华中医药学刊，2017，35（11）：2943-2945.
[27] 韩樱松，孙桂彬，冯瑾.放化疗联合生物靶向治疗对乳腺癌早期改良根治术后患者远期生存率的影响[J].实用癌症杂志，2017，32（9）：1460-1463.
[28] 王佳妮，母予馨，李青，等.高复发风险早期乳腺癌患者行表阿霉素联合环磷酰胺序贯紫杉醇剂量密集辅助化疗的耐受性分析[J].中华肿瘤杂志，2019，41（5）：368-372.